FDA warns about adverse event reports it has received that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products.
FDA issues a clinical hold on a vTv Therapeutics Phase 3 trial (CATT1) involving cadisegliatin (XXX DE-ITALICIZE XXX)and its use in improving glycemic control in Type 1 diabetes patients.
FDA warns about adverse event reports it has received that may be related to overdoses due to dosing errors associated with compounded semaglutide injectable products.
FDA issues a clinical hold on a vTv Therapeutics Phase 3 trial (CATT1) involving cadisegliatin (XXX DE-ITALICIZE XXX)and its use in improving glycemic control in Type 1 diabetes patients.
A new CDRH blog post outlines key activities that should be taking place during the lifecycle of artificial intelligence-enabled medical devices.
FDA approves a Sun Pharmaceutical Industries NDA for Leqselvi (deuruxolitinib) 8 mg tablets for treating adults with severe alopecia areata.
